logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Nephrology & Urology drugs

    FiltersReset Filters
    30 results

    • adstiladrin

      (nadofaragene firadenovec-vncg)
      Ferring Pharmaceuticals
      Usage: ADSTILADRIN® is indicated for treating high-risk BCG-unresponsive non-Muscle Invasive Bladder Cancer (NMIBC) in adults, specifically for those with carcinoma in situ (CIS) with or without papillary tumors.

    • balversa

      (Erdafitinib)
      Janssen Products LP
      Usage: BALVERSA is indicated for treating adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with FGFR3 genetic alterations, following progression on at least one prior systemic therapy. Selection of patients must utilize an FDA-approved companion diagnostic. It is not recommended for those eligible for PD-1 or PD-L1 inhibitors.

    • detrol la

      (tolterodine tartrate)
      Viatris Specialty LLC
      Usage: DETROL LA Capsules are indicated for treating overactive bladder symptoms, including urge urinary incontinence, urgency, and frequency.

    • eligard

      (Leuprolide Acetate)
      TOLMAR Inc.
      Usage: ELIGARD® is indicated for the palliative treatment of advanced prostate cancer.

    • erleada

      (Apalutamide)
      Janssen Products, LP
      Usage: ERLEADA is indicated for treating metastatic castration-sensitive prostate cancer (mCSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC).

    • fetroja

      (Cefiderocol sulfate tosylate)
      Shionogi Inc.
      Usage: FETROJA® is indicated for patients aged 18 and older for treating complicated urinary tract infections (cUTIs) including pyelonephritis, and hospital-acquired/ventilator-associated bacterial pneumonia, caused by susceptible Gram-negative bacteria like E. coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Use should limit drug resistance.

    • firmagon

      (Degarelix)
      Ferring Pharmaceuticals Inc.
      Usage: FIRMAGON® is indicated for the treatment of patients with advanced prostate cancer.

    • gemtesa

      (vibegron)
      Sumitomo Pharma America, Inc.
      Usage: GEMTESA® is indicated for the treatment of overactive bladder (OAB) in adults, characterized by urge urinary incontinence, urgency, and urinary frequency. It is also indicated for adult males with OAB symptoms who are undergoing pharmacological therapy for benign prostatic hyperplasia (BPH).

    • injectafer

      (Ferric Carboxymaltose Injection)
      American Regent, Inc.
      Usage: Injectafer is indicated for treating iron deficiency anemia in patients aged 1 year and older with oral iron intolerance or unsatisfactory response, and in non-dialysis dependent chronic kidney disease. It also treats iron deficiency in adults with heart failure (NYHA class II/III) to improve exercise capacity.

    • invokamet

      (canagliflozin and metformin hydrochloride)
      Janssen Pharmaceuticals, Inc.
      Usage: INVOKAMET and INVOKAMET XR are indicated as adjuncts to diet and exercise for improving glycemic control in adults and pediatric patients aged 10 and older with type 2 diabetes mellitus. Canagliflozin component reduces risks of major cardiovascular events and kidney disease in specific patient populations.